Cargando…
Impact of compensated cirrhosis on survival in patients with acute-on-chronic liver failure
BACKGROUND AND AIMS: Acute-on-chronic liver failure (ACLF) is considered a main prognostic event in patients with chronic liver disease (CLD). We analyzed the 28-day and 90-day mortality in ACLF patients with or without underlying cirrhosis enrolled in the ACLF Research Consortium (AARC) database. M...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer India
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8844167/ https://www.ncbi.nlm.nih.gov/pubmed/34822057 http://dx.doi.org/10.1007/s12072-021-10266-8 |
_version_ | 1784651421301342208 |
---|---|
author | Thanapirom, Kessarin Teerasarntipan, Tongluk Treeprasertsuk, Sombat Choudhury, Ashok Sahu, Manoj K. Maiwall, Rakhi Pamecha, Viniyendra Moreau, Richard Al Mahtab, Mamun Chawla, Yogesh Kumar Devarbhavi, Harshad Yu, Chen Ning, Qin Amarapurkar, Deepak Eapen, Chundamannil E. Hamid, Saeed Sadiq Butt, Amna Subhan Kim, Dong Joon Lee, Guan H. Sood, Ajit Lesmana, Laurentious A. Abbas, Zaigham Shiha, Gamal Payawal, Diana A. Yuen, Man-Fung Chan, Albert Lau, George Jia, Jidong Rahman, Salimur Sharma, Barjesh C. Yokosuka, Osamu Sarin, Shiv Kumar |
author_facet | Thanapirom, Kessarin Teerasarntipan, Tongluk Treeprasertsuk, Sombat Choudhury, Ashok Sahu, Manoj K. Maiwall, Rakhi Pamecha, Viniyendra Moreau, Richard Al Mahtab, Mamun Chawla, Yogesh Kumar Devarbhavi, Harshad Yu, Chen Ning, Qin Amarapurkar, Deepak Eapen, Chundamannil E. Hamid, Saeed Sadiq Butt, Amna Subhan Kim, Dong Joon Lee, Guan H. Sood, Ajit Lesmana, Laurentious A. Abbas, Zaigham Shiha, Gamal Payawal, Diana A. Yuen, Man-Fung Chan, Albert Lau, George Jia, Jidong Rahman, Salimur Sharma, Barjesh C. Yokosuka, Osamu Sarin, Shiv Kumar |
author_sort | Thanapirom, Kessarin |
collection | PubMed |
description | BACKGROUND AND AIMS: Acute-on-chronic liver failure (ACLF) is considered a main prognostic event in patients with chronic liver disease (CLD). We analyzed the 28-day and 90-day mortality in ACLF patients with or without underlying cirrhosis enrolled in the ACLF Research Consortium (AARC) database. METHODS: A total of 1,621 patients were prospectively enrolled and 637 (39.3%) of these patients had cirrhosis. Baseline characteristics, complications and mortality were compared between patients with and without cirrhosis. RESULTS: Alcohol consumption was more common in cirrhosis than non-cirrhosis (66.4% vs. 44.2%, p < 0.0001), while non-alcoholic fatty liver disease/cryptogenic CLD (10.9% vs 5.8%, p < 0.0001) and chronic HBV reactivation (18.8% vs 11.8%, p < 0.0001) were more common in non-cirrhosis. Only 0.8% of patients underwent liver transplantation. Overall, 28-day and 90-day mortality rates were 39.3% and 49.9%, respectively. Patients with cirrhosis had a greater chance of survival compared to those without cirrhosis both at 28-day (HR = 0.48; 95% CI 0.36–0.63, p < 0.0001) and 90-day (HR = 0.56; 95% CI 0.43–0.72, p < 0.0001), respectively. In alcohol CLD, non-cirrhosis patients had a higher 28-day (49.9% vs. 23.6%, p < 0.001) and 90-day (58.4% vs. 35.2%, p < 0.001) mortality rate than cirrhosis patients. ACLF patients with cirrhosis had longer mean survival than non-cirrhosis patients (25.5 vs. 18.8 days at 28-day and 65.2 vs. 41.2 days at 90-day). Exaggerated systemic inflammation might be the reason why non-cirrhosis patients had a poorer prognosis than those with cirrhosis after ACLF had occurred. CONCLUSIONS: The 28-day and 90-day mortality rates of ACLF patients without cirrhosis were significantly higher than those with cirrhosis in alcoholic CLD. The presence of cirrhosis and its stage should be evaluated at baseline to guide for management. Thai Clinical Trials Registry, TCTR20191226002. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12072-021-10266-8. |
format | Online Article Text |
id | pubmed-8844167 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer India |
record_format | MEDLINE/PubMed |
spelling | pubmed-88441672022-02-23 Impact of compensated cirrhosis on survival in patients with acute-on-chronic liver failure Thanapirom, Kessarin Teerasarntipan, Tongluk Treeprasertsuk, Sombat Choudhury, Ashok Sahu, Manoj K. Maiwall, Rakhi Pamecha, Viniyendra Moreau, Richard Al Mahtab, Mamun Chawla, Yogesh Kumar Devarbhavi, Harshad Yu, Chen Ning, Qin Amarapurkar, Deepak Eapen, Chundamannil E. Hamid, Saeed Sadiq Butt, Amna Subhan Kim, Dong Joon Lee, Guan H. Sood, Ajit Lesmana, Laurentious A. Abbas, Zaigham Shiha, Gamal Payawal, Diana A. Yuen, Man-Fung Chan, Albert Lau, George Jia, Jidong Rahman, Salimur Sharma, Barjesh C. Yokosuka, Osamu Sarin, Shiv Kumar Hepatol Int Original Article BACKGROUND AND AIMS: Acute-on-chronic liver failure (ACLF) is considered a main prognostic event in patients with chronic liver disease (CLD). We analyzed the 28-day and 90-day mortality in ACLF patients with or without underlying cirrhosis enrolled in the ACLF Research Consortium (AARC) database. METHODS: A total of 1,621 patients were prospectively enrolled and 637 (39.3%) of these patients had cirrhosis. Baseline characteristics, complications and mortality were compared between patients with and without cirrhosis. RESULTS: Alcohol consumption was more common in cirrhosis than non-cirrhosis (66.4% vs. 44.2%, p < 0.0001), while non-alcoholic fatty liver disease/cryptogenic CLD (10.9% vs 5.8%, p < 0.0001) and chronic HBV reactivation (18.8% vs 11.8%, p < 0.0001) were more common in non-cirrhosis. Only 0.8% of patients underwent liver transplantation. Overall, 28-day and 90-day mortality rates were 39.3% and 49.9%, respectively. Patients with cirrhosis had a greater chance of survival compared to those without cirrhosis both at 28-day (HR = 0.48; 95% CI 0.36–0.63, p < 0.0001) and 90-day (HR = 0.56; 95% CI 0.43–0.72, p < 0.0001), respectively. In alcohol CLD, non-cirrhosis patients had a higher 28-day (49.9% vs. 23.6%, p < 0.001) and 90-day (58.4% vs. 35.2%, p < 0.001) mortality rate than cirrhosis patients. ACLF patients with cirrhosis had longer mean survival than non-cirrhosis patients (25.5 vs. 18.8 days at 28-day and 65.2 vs. 41.2 days at 90-day). Exaggerated systemic inflammation might be the reason why non-cirrhosis patients had a poorer prognosis than those with cirrhosis after ACLF had occurred. CONCLUSIONS: The 28-day and 90-day mortality rates of ACLF patients without cirrhosis were significantly higher than those with cirrhosis in alcoholic CLD. The presence of cirrhosis and its stage should be evaluated at baseline to guide for management. Thai Clinical Trials Registry, TCTR20191226002. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12072-021-10266-8. Springer India 2021-11-25 /pmc/articles/PMC8844167/ /pubmed/34822057 http://dx.doi.org/10.1007/s12072-021-10266-8 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Thanapirom, Kessarin Teerasarntipan, Tongluk Treeprasertsuk, Sombat Choudhury, Ashok Sahu, Manoj K. Maiwall, Rakhi Pamecha, Viniyendra Moreau, Richard Al Mahtab, Mamun Chawla, Yogesh Kumar Devarbhavi, Harshad Yu, Chen Ning, Qin Amarapurkar, Deepak Eapen, Chundamannil E. Hamid, Saeed Sadiq Butt, Amna Subhan Kim, Dong Joon Lee, Guan H. Sood, Ajit Lesmana, Laurentious A. Abbas, Zaigham Shiha, Gamal Payawal, Diana A. Yuen, Man-Fung Chan, Albert Lau, George Jia, Jidong Rahman, Salimur Sharma, Barjesh C. Yokosuka, Osamu Sarin, Shiv Kumar Impact of compensated cirrhosis on survival in patients with acute-on-chronic liver failure |
title | Impact of compensated cirrhosis on survival in patients with acute-on-chronic liver failure |
title_full | Impact of compensated cirrhosis on survival in patients with acute-on-chronic liver failure |
title_fullStr | Impact of compensated cirrhosis on survival in patients with acute-on-chronic liver failure |
title_full_unstemmed | Impact of compensated cirrhosis on survival in patients with acute-on-chronic liver failure |
title_short | Impact of compensated cirrhosis on survival in patients with acute-on-chronic liver failure |
title_sort | impact of compensated cirrhosis on survival in patients with acute-on-chronic liver failure |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8844167/ https://www.ncbi.nlm.nih.gov/pubmed/34822057 http://dx.doi.org/10.1007/s12072-021-10266-8 |
work_keys_str_mv | AT thanapiromkessarin impactofcompensatedcirrhosisonsurvivalinpatientswithacuteonchronicliverfailure AT teerasarntipantongluk impactofcompensatedcirrhosisonsurvivalinpatientswithacuteonchronicliverfailure AT treeprasertsuksombat impactofcompensatedcirrhosisonsurvivalinpatientswithacuteonchronicliverfailure AT choudhuryashok impactofcompensatedcirrhosisonsurvivalinpatientswithacuteonchronicliverfailure AT sahumanojk impactofcompensatedcirrhosisonsurvivalinpatientswithacuteonchronicliverfailure AT maiwallrakhi impactofcompensatedcirrhosisonsurvivalinpatientswithacuteonchronicliverfailure AT pamechaviniyendra impactofcompensatedcirrhosisonsurvivalinpatientswithacuteonchronicliverfailure AT moreaurichard impactofcompensatedcirrhosisonsurvivalinpatientswithacuteonchronicliverfailure AT almahtabmamun impactofcompensatedcirrhosisonsurvivalinpatientswithacuteonchronicliverfailure AT chawlayogeshkumar impactofcompensatedcirrhosisonsurvivalinpatientswithacuteonchronicliverfailure AT devarbhaviharshad impactofcompensatedcirrhosisonsurvivalinpatientswithacuteonchronicliverfailure AT yuchen impactofcompensatedcirrhosisonsurvivalinpatientswithacuteonchronicliverfailure AT ningqin impactofcompensatedcirrhosisonsurvivalinpatientswithacuteonchronicliverfailure AT amarapurkardeepak impactofcompensatedcirrhosisonsurvivalinpatientswithacuteonchronicliverfailure AT eapenchundamannile impactofcompensatedcirrhosisonsurvivalinpatientswithacuteonchronicliverfailure AT hamidsaeedsadiq impactofcompensatedcirrhosisonsurvivalinpatientswithacuteonchronicliverfailure AT buttamnasubhan impactofcompensatedcirrhosisonsurvivalinpatientswithacuteonchronicliverfailure AT kimdongjoon impactofcompensatedcirrhosisonsurvivalinpatientswithacuteonchronicliverfailure AT leeguanh impactofcompensatedcirrhosisonsurvivalinpatientswithacuteonchronicliverfailure AT soodajit impactofcompensatedcirrhosisonsurvivalinpatientswithacuteonchronicliverfailure AT lesmanalaurentiousa impactofcompensatedcirrhosisonsurvivalinpatientswithacuteonchronicliverfailure AT abbaszaigham impactofcompensatedcirrhosisonsurvivalinpatientswithacuteonchronicliverfailure AT shihagamal impactofcompensatedcirrhosisonsurvivalinpatientswithacuteonchronicliverfailure AT payawaldianaa impactofcompensatedcirrhosisonsurvivalinpatientswithacuteonchronicliverfailure AT yuenmanfung impactofcompensatedcirrhosisonsurvivalinpatientswithacuteonchronicliverfailure AT chanalbert impactofcompensatedcirrhosisonsurvivalinpatientswithacuteonchronicliverfailure AT laugeorge impactofcompensatedcirrhosisonsurvivalinpatientswithacuteonchronicliverfailure AT jiajidong impactofcompensatedcirrhosisonsurvivalinpatientswithacuteonchronicliverfailure AT rahmansalimur impactofcompensatedcirrhosisonsurvivalinpatientswithacuteonchronicliverfailure AT sharmabarjeshc impactofcompensatedcirrhosisonsurvivalinpatientswithacuteonchronicliverfailure AT yokosukaosamu impactofcompensatedcirrhosisonsurvivalinpatientswithacuteonchronicliverfailure AT sarinshivkumar impactofcompensatedcirrhosisonsurvivalinpatientswithacuteonchronicliverfailure AT impactofcompensatedcirrhosisonsurvivalinpatientswithacuteonchronicliverfailure |